Collapsing glomerulopathy in a renal transplant recipient: Potential molecular mechanisms

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: In this case report, we describe a predisposed renal transplant patient who developed FSGS with cellular and collapsing features after sirolimus exposure and discuss the potential molecular mechanisms. Case Report A 35-year old African American female with end stage renal disease due to lupus nephritis received a living related renal transplant from a brother. She had immediate function achieved serum creatinine level of 1.7 mg/dl post day 4. Following a slow rise in the creatinine, first renal allograft biopsy performed on post op day 14 that showed thrombotic microangiopathy (TMA) involving arterioles and glomerular capillaries without any sign of rejection. The serological work up was negative for donor specific and antiphospholipid antibodies. The TMA was attributed to tacrolimus which was subsequently discontinued. It was replaced with sirolimus with loading dose of 10mg once and then 5 mg daily maintenance dose at day 21. At day 35, the patient was noted to have nephrotic range proteinuria, 12 gm/24 hrs. A second renal biopsy performed that revealed de novo focal segmental glomerulosclerosis with cellular and collapsing features, mild mesangial proliferative glomerulonephritis with immunoflourescence consistent with early recurrence of lupus nephritis ISN/RPS class 2. The etiology of cellular and collapsing FSGS was thought to be related to sirolimus based on timing of exposure and negative work up for secondary causes of collapsing FSGS. Sirolimus was switched to cyclosporine. At day 105, proteinuria decreased to 1.6 grams/day and serum creatinine leveled off 1.6 mg/dL. Conclusions: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.

Original languageEnglish (US)
Pages (from-to)113-116
Number of pages4
JournalAnnals of Transplantation
Volume16
Issue number2
StatePublished - 2011

Fingerprint

Sirolimus
Thrombotic Microangiopathies
Kidney
Creatinine
Lupus Nephritis
Proteinuria
Transplants
Biopsy
Focal Segmental Glomerulosclerosis
Antiphospholipid Antibodies
Arterioles
Tacrolimus
Glomerulonephritis
Serum
African Americans
Cyclosporine
Chronic Kidney Failure
Allografts
Siblings
Transplant Recipients

Keywords

  • Cellular and collapsing variant
  • Focal segmental glomerulosclerosis
  • Kidney transplantation
  • Podocytopathy
  • Renal biopsy
  • Sirolimus
  • WT1 expression

ASJC Scopus subject areas

  • Transplantation

Cite this

Collapsing glomerulopathy in a renal transplant recipient : Potential molecular mechanisms. / Dogan, Ekrem; Ghanta, Mythili; Tanriover, Bekir.

In: Annals of Transplantation, Vol. 16, No. 2, 2011, p. 113-116.

Research output: Contribution to journalArticle

@article{a9b3d8b98ab346ee897eae69ffed43ed,
title = "Collapsing glomerulopathy in a renal transplant recipient: Potential molecular mechanisms",
abstract = "Background: In this case report, we describe a predisposed renal transplant patient who developed FSGS with cellular and collapsing features after sirolimus exposure and discuss the potential molecular mechanisms. Case Report A 35-year old African American female with end stage renal disease due to lupus nephritis received a living related renal transplant from a brother. She had immediate function achieved serum creatinine level of 1.7 mg/dl post day 4. Following a slow rise in the creatinine, first renal allograft biopsy performed on post op day 14 that showed thrombotic microangiopathy (TMA) involving arterioles and glomerular capillaries without any sign of rejection. The serological work up was negative for donor specific and antiphospholipid antibodies. The TMA was attributed to tacrolimus which was subsequently discontinued. It was replaced with sirolimus with loading dose of 10mg once and then 5 mg daily maintenance dose at day 21. At day 35, the patient was noted to have nephrotic range proteinuria, 12 gm/24 hrs. A second renal biopsy performed that revealed de novo focal segmental glomerulosclerosis with cellular and collapsing features, mild mesangial proliferative glomerulonephritis with immunoflourescence consistent with early recurrence of lupus nephritis ISN/RPS class 2. The etiology of cellular and collapsing FSGS was thought to be related to sirolimus based on timing of exposure and negative work up for secondary causes of collapsing FSGS. Sirolimus was switched to cyclosporine. At day 105, proteinuria decreased to 1.6 grams/day and serum creatinine leveled off 1.6 mg/dL. Conclusions: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.",
keywords = "Cellular and collapsing variant, Focal segmental glomerulosclerosis, Kidney transplantation, Podocytopathy, Renal biopsy, Sirolimus, WT1 expression",
author = "Ekrem Dogan and Mythili Ghanta and Bekir Tanriover",
year = "2011",
language = "English (US)",
volume = "16",
pages = "113--116",
journal = "Annals of Transplantation",
issn = "1425-9524",
publisher = "International Scientific Information, Inc.",
number = "2",

}

TY - JOUR

T1 - Collapsing glomerulopathy in a renal transplant recipient

T2 - Potential molecular mechanisms

AU - Dogan, Ekrem

AU - Ghanta, Mythili

AU - Tanriover, Bekir

PY - 2011

Y1 - 2011

N2 - Background: In this case report, we describe a predisposed renal transplant patient who developed FSGS with cellular and collapsing features after sirolimus exposure and discuss the potential molecular mechanisms. Case Report A 35-year old African American female with end stage renal disease due to lupus nephritis received a living related renal transplant from a brother. She had immediate function achieved serum creatinine level of 1.7 mg/dl post day 4. Following a slow rise in the creatinine, first renal allograft biopsy performed on post op day 14 that showed thrombotic microangiopathy (TMA) involving arterioles and glomerular capillaries without any sign of rejection. The serological work up was negative for donor specific and antiphospholipid antibodies. The TMA was attributed to tacrolimus which was subsequently discontinued. It was replaced with sirolimus with loading dose of 10mg once and then 5 mg daily maintenance dose at day 21. At day 35, the patient was noted to have nephrotic range proteinuria, 12 gm/24 hrs. A second renal biopsy performed that revealed de novo focal segmental glomerulosclerosis with cellular and collapsing features, mild mesangial proliferative glomerulonephritis with immunoflourescence consistent with early recurrence of lupus nephritis ISN/RPS class 2. The etiology of cellular and collapsing FSGS was thought to be related to sirolimus based on timing of exposure and negative work up for secondary causes of collapsing FSGS. Sirolimus was switched to cyclosporine. At day 105, proteinuria decreased to 1.6 grams/day and serum creatinine leveled off 1.6 mg/dL. Conclusions: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.

AB - Background: In this case report, we describe a predisposed renal transplant patient who developed FSGS with cellular and collapsing features after sirolimus exposure and discuss the potential molecular mechanisms. Case Report A 35-year old African American female with end stage renal disease due to lupus nephritis received a living related renal transplant from a brother. She had immediate function achieved serum creatinine level of 1.7 mg/dl post day 4. Following a slow rise in the creatinine, first renal allograft biopsy performed on post op day 14 that showed thrombotic microangiopathy (TMA) involving arterioles and glomerular capillaries without any sign of rejection. The serological work up was negative for donor specific and antiphospholipid antibodies. The TMA was attributed to tacrolimus which was subsequently discontinued. It was replaced with sirolimus with loading dose of 10mg once and then 5 mg daily maintenance dose at day 21. At day 35, the patient was noted to have nephrotic range proteinuria, 12 gm/24 hrs. A second renal biopsy performed that revealed de novo focal segmental glomerulosclerosis with cellular and collapsing features, mild mesangial proliferative glomerulonephritis with immunoflourescence consistent with early recurrence of lupus nephritis ISN/RPS class 2. The etiology of cellular and collapsing FSGS was thought to be related to sirolimus based on timing of exposure and negative work up for secondary causes of collapsing FSGS. Sirolimus was switched to cyclosporine. At day 105, proteinuria decreased to 1.6 grams/day and serum creatinine leveled off 1.6 mg/dL. Conclusions: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.

KW - Cellular and collapsing variant

KW - Focal segmental glomerulosclerosis

KW - Kidney transplantation

KW - Podocytopathy

KW - Renal biopsy

KW - Sirolimus

KW - WT1 expression

UR - http://www.scopus.com/inward/record.url?scp=79960104742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960104742&partnerID=8YFLogxK

M3 - Article

C2 - 21716195

AN - SCOPUS:79960104742

VL - 16

SP - 113

EP - 116

JO - Annals of Transplantation

JF - Annals of Transplantation

SN - 1425-9524

IS - 2

ER -